candesartan has been researched along with Renal Artery Stenosis in 2 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Atherosclerotic renal artery stenosis is a problem with no consensus on diagnosis or therapy." | 1.33 | Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. ( Cohen, DJ; Cooper, CJ; D'Agostino, R; Dworkin, L; Henrich, W; Jaff, M; Jamerson, K; Kuntz, R; Matsumoto, A; Murphy, TP; Reid, D; Rosenfield, K; Rundback, J; Steffes, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoshide, S | 1 |
| Kario, K | 1 |
| Shimada, K | 1 |
| Cooper, CJ | 1 |
| Murphy, TP | 1 |
| Matsumoto, A | 1 |
| Steffes, M | 1 |
| Cohen, DJ | 1 |
| Jaff, M | 1 |
| Kuntz, R | 1 |
| Jamerson, K | 1 |
| Reid, D | 1 |
| Rosenfield, K | 1 |
| Rundback, J | 1 |
| D'Agostino, R | 1 |
| Henrich, W | 1 |
| Dworkin, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)[NCT00081731] | Phase 3 | 947 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 77 |
| Stenting | 68 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 20 |
| Stenting | 20 |
Only the first event per participant is included in the composite (NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 169 |
| Stenting | 161 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 26 |
| Stenting | 27 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 27 |
| Stenting | 30 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 3 |
| Stenting | 4 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 16 |
| Stenting | 12 |
2 other studies available for candesartan and Renal Artery Stenosis
| Article | Year |
|---|---|
Ischemic nephropathy in an elderly patient.
Topics: Aged; Antihypertensive Agents; Atherosclerosis; Benzimidazoles; Biphenyl Compounds; Female; Humans; | 2008 |
Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial.
Topics: Angioplasty, Balloon; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Benzimidazoles; Biph | 2006 |